Analysis of US FDA-Approved Drugs Containing Sulfur Atoms

[1]  E. Ottesen,et al.  ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy , 2017, Translational neuroscience.

[2]  G. Plosker.  Acamprosate: A Review of Its Use in Alcohol Dependence , 2015, Drugs.

[3]  Sunjoo Ahn,et al.  Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats , 2015, Archives of pharmacal research.

[4]  J. T. Njardarson,et al.  Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery. , 2014, Journal of medicinal chemistry.

[5]  S. Parthasarathy,et al.  Sugammadex: A revolutionary drug in neuromuscular pharmacology , 2013, Anesthesia, essays and researches.

[6]  N. Swerdlow,et al.  Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats , 2012, Brain Research.

[7]  A. Halabi,et al.  Macitentan: entry-into-humans study with a new endothelin receptor antagonist , 2011, European Journal of Clinical Pharmacology.

[8]  Jun Li,et al.  Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review , 2010, Rheumatology International.

[9]  M. Bianchi.  Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications. , 2010, Medical hypotheses.

[10]  D. Mukherjee,et al.  Emerging P2Y12 receptor antagonists: role in coronary artery disease. , 2010, Current vascular pharmacology.

[11]  L. Wallentin.  P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. , 2009, European heart journal.

[12]  L. Kamen,et al.  A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury , 2008 .

[13]  T. Andersson,et al.  Stereoselective Disposition of Proton Pump Inhibitors , 2008, Clinical drug investigation.

[14]  G. Perigli,et al.  Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. , 2007, The Journal of endocrinology.

[15]  G. Elion,et al.  The purine path to chemotherapy , 1989, In Vitro Cellular & Developmental Biology.

[16]  L. Kvols,et al.  Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. , 2006, Anti-cancer drugs.

[17]  L. H. Hansen,et al.  Interaction of Pleuromutilin Derivatives with the Ribosomal Peptidyl Transferase Center , 2006, Antimicrobial Agents and Chemotherapy.

[18]  E. Maltezos,et al.  Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. , 2006, Anti-cancer drugs.

[19]  J. Corbin,et al.  Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5) , 2004, Neurochemistry International.

[20]  G. Sachs,et al.  Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. , 2004, Journal of the American Chemical Society.

[21]  A. Lang,et al.  Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists , 2004, Movement disorders : official journal of the Movement Disorder Society.

[22]  H. Mulder,et al.  Extrapancreatic insulin effect of glibenclamide , 1991, European Journal of Clinical Pharmacology.

[23]  S. Kunapuli,et al.  Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. , 2003, Blood.

[24]  L. Scott,et al.  Emtricitabine , 2012, Drugs.

[25]  H. Nagashima.  Studies on the Different Modes of Action of the Anticoagulant Protease Inhibitors DX-9065a and Argatroban , 2002, The Journal of Biological Chemistry.

[26]  J. Caldwell,et al.  Putting chirality to work: the strategy of chiral switches , 2002, Nature Reviews Drug Discovery.

[27]  W. Gahl,et al.  Cystinosis. , 2002, The New England journal of medicine.

[28]  A. Hall,et al.  The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. , 2002, Molecular pharmacology.

[29]  M. Gottesman,et al.  Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. , 2002, Molecular pharmacology.

[30]  H. Nader,et al.  Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates. , 2000, Biochimica et biophysica acta.

[31]  A. Seeling,et al.  Wichtige pharmazeutisch-chemische Eigenschaften des zentralen Muskelrelaxans Chlormezanon , 2000 .

[32]  W. Shen.  A history of antipsychotic drug development. , 1999, Comprehensive psychiatry.

[33]  U. Panten,et al.  Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes , 1999, British journal of pharmacology.

[34]  P. Blanchet.  Rationale for Use of Dopamine Agonists in Parkinson's Disease: Review of Ergot Derivatives , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[35]  T. Humphries,et al.  Review article: drug interactions with agents used to treat acid‐related diseases , 1999, Alimentary pharmacology & therapeutics.

[36]  H. Diener,et al.  Acute management of migraine: triptans and beyond. , 1999, Current opinion in neurology.

[37]  G. Sachs,et al.  Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents* , 1997, The Journal of Biological Chemistry.

[38]  V. Kapur,et al.  Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis , 1997, Journal of bacteriology.

[39]  G. Busatto,et al.  Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia , 1997, Journal of psychopharmacology.

[40]  E. Corey,et al.  Enantioselective Total Synthesis of Ecteinascidin 743 , 1996 .

[41]  Khan W. Li,et al.  Total Synthesis of the Antitumor Depsipeptide FR-901,228 , 1996 .

[42]  J. Bryan,et al.  A Family of Sulfonylurea Receptors Determines the Pharmacological Properties of ATP-Sensitive K+ Channels , 1996, Neuron.

[43]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[44]  M. Okuhara,et al.  FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. , 1994, The Journal of antibiotics.

[45]  R. Steudel,et al.  Cyclic selenium sulfides , 1982 .

[46]  S. Hecht,et al.  Total synthesis of bleomycin , 1982 .

[47]  M. Muroi,et al.  Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin , 1981, Nature.

[48]  A. Taurog,et al.  The mechanism of action of the thioureylene antithyroid drugs. , 1976, Endocrinology.

[49]  T. Maren,et al.  Relatons between structure and biological activity of sulfonamides. , 1976, Annual review of pharmacology and toxicology.

[50]  G. Bonadonna,et al.  Clinical trials with bleomycin in lymphomas and in solid tumors. , 1972, European journal of cancer.

[51]  S. Snyder,et al.  Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. K. Seydel.  Sulfonamides, structure-activity relationship, and mode of action. Structural problems of the antibacterial action of 4-aminobenzoic acid (PABA) antagonists. , 1968, Journal of pharmaceutical sciences.

[53]  P. Brunel,et al.  [Identification of 3 new metabolites of ethionamide: chromatography, spectrophotometry, polarography]. , 1966, Annales pharmaceutiques francaises.

[54]  E. Abraham,et al.  The structure of cephalosporin C , 1961 .

[55]  J. Sprague.  THE CHEMISTRY OF DIURETICS , 1958, Annals of the New York Academy of Sciences.

[56]  S. P. Massie.  The Chemistry of Phenothiazine. , 1954 .

[57]  J. Delay,et al.  [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. , 1952, Annales medico-psychologiques.

[58]  E. Jacobsen,et al.  Site of the formation of acetaldehyde after ingestion of antabuse (tetraethylthiuramdisulphide) and alcohol. , 2009, Acta pharmacologica et toxicologica.